title: Dexamethasone, paclitaxel, etoposide, cyclophosphamide (d-TEC) and G-CSF for stem cell mobilisation in multiple myeloma.
abstract: Forty-one patients with multiple myeloma were treated with a novel stem cell mobilisation regimen. The primary end points were adequate stem cell mobilising ability (>1% circulating CD34-positive cells) and collection (> or = 4 x 10(6) CD34-positive cells/kg), and safety. The secondary end point was activity against myeloma. The regimen (d-TEC) consisted of dexamethasone, paclitaxel 200 mg/m(2) i.v., etoposide 60 mg/kg i.v., cyclophosphamide 3 g/m(2) i.v., and G-CSF 5-10 microg/kg/day i.v. A total of 84 cycles were administered to these 41 individuals. Patient characteristics included a median age of 53 years, a median of five prior chemotherapy cycles, and a median interval of 10 months from diagnosis of myeloma to first cycle of d-TEC. Seventy-five percent of the patients had stage II or III disease, 50% had received carmustine and/or melphalan previously, and 25% had received prior radiation therapy. Eighty-eight percent of patients mobilised adequately after the first cycle of d-TEC and 91% mobilized adequately after the second cycle. An adequate number of stem cells were collected in 32 patients. Of the remaining nine patients, three mobilised, but stem cells were not collected, two mobilised but stem cell collection was < 4 x 10(6) CD34-positive cells/kg, three did not mobilise, and one died of disease progression. Major toxicities included pancytopenia, alopecia, fever and stomatitis. One patient died from multi-organ failure and progressive disease. Fifty percent of evaluable patients demonstrated a partial response and 28.6% of patients had a minor response. This novel dose-intense regimen was safe, capable of stem cell mobilisation and collection, even in heavily pre-treated patients, and active against the underlying myeloma.
authors.affiliation: Bone Marrow Transplant Program, University of Connecticut Health Center, Farmington, CT 06030, USA.
authors.forename: S
authors.initials: S
authors.lastname: Bilgrami
authors.forename: R D
authors.initials: RD
authors.lastname: Bona
authors.forename: R L
authors.initials: RL
authors.lastname: Edwards
authors.forename: Z
authors.initials: Z
authors.lastname: Li
authors.forename: B
authors.initials: B
authors.lastname: Naqvi
authors.forename: A
authors.initials: A
authors.lastname: Shaikh
authors.forename: F
authors.initials: F
authors.lastname: Furlong
authors.forename: J
authors.initials: J
authors.lastname: Fox
authors.forename: J
authors.initials: J
authors.lastname: Clive
authors.forename: P J
authors.initials: PJ
authors.lastname: Tutschka
mesh_terms: D000328:Adult; D000368:Aged; D000932:Antiemetics / Q000627:therapeutic use; D015703:Antigens, CD / Q000097:blood; D018952:Antigens, CD34 / Q000097:blood; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D003131:Combined Modality Therapy; D003520:Cyclophosphamide / Q000008:administration & dosage; D003907:Dexamethasone / Q000008:administration & dosage / Q000627:therapeutic use*; D004334:Drug Administration Schedule; D005047:Etoposide / Q000008:administration & dosage; D005260:Female; D016179:Granulocyte Colony-Stimulating Factor / Q000627:therapeutic use*; D019650:Hematopoietic Stem Cell Mobilization / Q000379:methods*; D006801:Humans; D007937:Leukapheresis; D008140:Lorazepam / Q000627:therapeutic use; D008297:Male; D008875:Middle Aged; D009101:Multiple Myeloma / Q000628:therapy*; D017294:Ondansetron / Q000627:therapeutic use; D017239:Paclitaxel / Q000008:administration & dosage; D043823:Taxoids; D014182:Transplantation, Autologous
chemical_list: D000932:Antiemetics; D015703:Antigens, CD; D018952:Antigens, CD34; D043823:Taxoids; D016179:Granulocyte Colony-Stimulating Factor; D017294:Ondansetron; D005047:Etoposide; D003907:Dexamethasone; D003520:Cyclophosphamide; D008140:Lorazepam; D017239:Paclitaxel